Melissa McCracken

Melissa McCracken, PhD, serves as a Board Member for A2 Biotherapeutics, Inc., Tyra Biosciences, Ambagon Therapeutics, Alpha-9 Theranostics Inc., K36 Therapeutics, and Alterome Therapeutics, reflecting extensive involvement in the biotechnology and oncology sectors. As a Partner and Principal at Nextech Invest, a venture capital firm specializing in cancer therapeutics, McCracken contributes to precision medicine approaches in oncology. McCracken's prior roles include Board Observer positions at ProfoundBio and IconOVir Bio and being a Kauffman Fellows Class of 25 Fellow. Academic credentials include a PhD in Molecular and Medical Pharmacology from the University of California, Los Angeles, and a BS in Biochemistry from the University of California, Davis.